MedTrace Logo

Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin

NCT01544751 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2014-05-28

No results posted yet for this study

Summary

The first line approach to NAFLD is currently based on diet and lifestyle modification. Aim of our Unit is to compare the efficacy of two different doses of metformin (1 g/day and 2 g/day) with atorvastatin (20 mg/day) on amelioration of inflammatory and cardiometabolic parameters, ultrasound signs and clinical scores associated with liver fibrosis in early-stage NAFLD non-diabetic patients.

Conditions

  • Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

Low dose metformin

500 mg twice a day

DRUG

Metformin

1000 mg twice a day

DRUG

Atorvastatin

20 mg/day

Sponsors & Collaborators

  • Prof Antonino Belfiore

    lead OTHER

Principal Investigators

  • Antonino Belfiore, Director · Endocrinology Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01544751 on ClinicalTrials.gov